Nucleocapsid Antibodies Appear to Be Long-Lasting After SARS-CoV-2 Infection

In a prospective, longitudinal study, N-antibodies peaked 90–100 days after infection and persisted for at least 500 days in most patients. The duration of antibody response after SARS-CoV-2 infection is not clearly established, although prior studies have estimated that antibodies produced after natural infection last from 3 to 6 months. […]

Read More

More Antibodies With Longer Intervals Between COVID Vaccine Doses

LISBON, Portugal — An overall ninefold increase in COVID-19 antibody levels can be seen with a longer interval between first and second doses of the Pfizer/BioNTech (BNT162b2) vaccine in people without prior infection, according to data from the UK government’s SIREN (SARS-CoV-2 Immunity and Reinfection Evaluation) study. This interval-dependent antibody […]

Read More

COVID19 Antibodies Improve for Months After mRNA Vaccine

Antibodies induced by mRNA COVID-19 vaccines keep improving in quality for at least six months while the immune system continues to “train” its antibody-producing B cells, according to a new study. After vaccination, some B cells become short-lived antibody-producing cells, while others join germinal centers in lymph nodes – essentially, […]

Read More

Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection

COVID-19 vaccination in pregnancy generates functional anti-spike (anti-S) IgG antibodies in maternal circulation that are detectable in umbilical cord blood at birth and can protect the newborn and infant from COVID-19.1-4 Anti-S IgG titers in the umbilical cord are correlated with maternal titers and are highest after late second and early […]

Read More

Questions Remain About Who Will Get Monoclonal Antibodies for COVID-19 Preexposure Prophylaxis

Every day for weeks this past fall, Brian Koffman, MD, would Google “AZD7442, AZD7442, AZD7442.” He finally hit pay dirt December 8, when he discovered that the US Food and Drug Administration had authorized AstraZeneca’s long-acting monoclonal antibody combination, AZD7442 (Evusheld), for COVID-19 preexposure prophylaxis in adults and children at least 12 years […]

Read More

Moderna’s Vaccine Creates Twice as Many Antibodies as Pfizer’s

Moderna’s COVID-19 vaccine generates more than double the antibodies seen from Pfizer’s COVID-19 vaccine, according to a new research letter published Monday in JAMA. The study compared the levels of antibodies produced against the coronavirus spike protein. However, the research didn’t measure the levels of neutralizing antibodies or whether the differences correlated with […]

Read More

In Rheumatic Disease, mRNA COVID-19 Vaccination More Likely Than J&J Shot to Generate Antibodies

(Reuters Health) – Patients with rheumatic and musculoskeletal diseases may be less likely to mount an antibody response to the Johnson and Johnson (J&J) COVID-19 vaccine compared with those who get an mRNA-based vaccine, a new study suggests. Data from a prospective cohort of 1,039 patients with rheumatic and musculoskeletal […]

Read More
Translate »